Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract
NCT00353015Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2003
- Primary completion
- Dec 2007
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, Cisplatin micelle injection (HA132) in gastrointestinal neuroendocrine carcinoma (GI-NEC), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2003; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabCisplatin micelle injection (HA132)
03
Conditions
gastrointestinal neuroendocrine carcinoma (GI-NEC)
Beyond the preview
Go deeper on NCT00353015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00353015.